AstraZeneca Heart Drug Shown to Reverse Heart Disease
Posted on: Tuesday, 14 March 2006, 15:00 CST
Data from a two-year study of AstraZeneca's heart drug Crestor has revealed that the drug reversed rather than delayed the plaque build-up in arteries associated with coronary artery disease.
The findings, presented at the 55th annual scientific session of the American College of Cardiology, mark the first time that a statin has demonstrated a regression in artery plaque build-up in a major clinical study.
The results also constitute a major victory for the AstraZeneca drug, which has previously lived in the shadow of Pfizer's much more successful statin, Lipitor.
The results from the trial showed that plaque build-up in patients' arteries was reduced by between 7% and 9%, with an associated 53% reduction in LDL-C, or 'bad' cholesterol, and a 15% increase in HDL-C, or 'good' cholesterol.
In the 507 patient study, patients who had evidence of coronary artery disease received a dose of Crestor four times higher than the usual dosage.
"The data from this study - demonstrating that Crestor regressed plaque in the arteries of four out of five patients - is an important new finding. We see this as underscoring the benefits of aggressively managing cholesterol levels, both LDL and HDL, to reduce the burden of atherosclerosis," said Dr Howard Hutchinson, vice president of clinical research for AstraZeneca.
Source: Datamonitor
Related Articles
- SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
- Results From Largest Statin Study of Patients With Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease
- Study Shows Lone Sickle Cell Drug is Underused
- Research and Markets: ''Building Patient Care Continuity With Prepared Practice Teams'' Audio Conference Now Available
- This Report Provides Insight into the Pipeline Status of Atherosclerosis or Coronary Artery Disease Drugs
- Study Sheds Light on Cancer Drug Mechanism
- Early Study Provides Evidence That Investigational Drug Phenoxodiol Targets Prostate Cancer Protein
- Web Seminar Offered -- ''EHR Case Study: Delivering Patient Data Today''
- Not Telling Patients About New Drugs is 'Unethical and Paternalistic'
 |
 |
User Comments (0)
RSS Feeds